June 12, 2017 / 12:48 PM / 2 months ago

BRIEF-Zosano Pharma updates on additional data from Zotrip study

June 12 (Reuters) - Zosano Pharma Corp:

* Says presents additional data from Zotrip study

* Zosano pharma says 3.8 mg dose of of M207 achieved significance in secondary endpoints of pain freedom at 45 minutes and 1 hour

* Says 3.8 mg dose of M207 showed durability of effect on pain freedom at 24 and 48 hours

* Data demonstrated that the results were attained with no serious adverse events and a favorable tolerability profile Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below